Chekka Lakshmi Manasa S, Langaee Taimour, Johnson Julie A
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, FL, United States.
Division of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL, United States.
Front Genet. 2022 Mar 31;13:836636. doi: 10.3389/fgene.2022.836636. eCollection 2022.
MicroRNAs are small noncoding RNAs with potential regulatory roles in hypertension and drug response. The presence of many of these RNAs in biofluids has spurred investigation into their role as possible biomarkers for use in precision approaches to healthcare. One of the major challenges in clinical translation of circulating miRNA biomarkers is the limited replication across studies due to lack of standards for data normalization techniques for array-based approaches and a lack of consensus on an endogenous control normalizer for qPCR-based candidate miRNA profiling studies. We conducted genome-wide profiling of 754 miRNAs in baseline plasma of 36 European American individuals with uncomplicated hypertension selected from the PEAR clinical trial, who had been untreated for hypertension for at least one month prior to sample collection. After appropriate quality control with amplification score and missingness filters, we tested different normalization strategies such as normalization with global mean of imputed and unimputed data, mean of restricted set of miRNAs, quantile normalization, and endogenous control miRNA normalization to identify the method that best reduces the technical/experimental variability in the data. We identified best endogenous control candidates with expression pattern closest to the mean miRNA expression in the sample, as well as by assessing their stability using a combination of NormFinder, geNorm, Best Keeper and Delta Ct algorithms under the Reffinder software. The suitability of the four best endogenous controls was validated in 50 hypertensive African Americans from the same trial with reverse-transcription-qPCR and by evaluating their stability ranking in that cohort. Among the compared normalization strategies, quantile normalization and global mean normalization performed better than others in terms of reducing the standard deviation of miRNAs across samples in the array-based data. Among the four strongest candidate miRNAs from our selection process (miR-223-3p, 19b, 106a, and 126-5p), miR-223-3p and miR-126-5p were consistently expressed with the best stability ranking in the validation cohort. Furthermore, the combination of miR-223-3p and 126-5p showed better stability ranking when compared to single miRNAs. We identified quantile normalization followed by global mean normalization to be the best methods in reducing the variance in the data. We identified the combination of miR-223-3p and 126-5p as potential endogenous control in studies of hypertension.
微小RNA是一类小的非编码RNA,在高血压和药物反应中具有潜在的调节作用。生物流体中存在许多这类RNA,这促使人们对其作为精准医疗中可能的生物标志物的作用进行研究。循环miRNA生物标志物临床转化的主要挑战之一是,由于基于阵列的方法缺乏数据标准化技术标准,以及基于qPCR的候选miRNA分析研究缺乏内参标准化的共识,导致各研究间的重复性有限。我们对从PEAR临床试验中选取的36名未经治疗的单纯性高血压欧美个体的基线血浆中的754种miRNA进行了全基因组分析,这些个体在样本采集前至少一个月未接受高血压治疗。在使用扩增分数和缺失值过滤器进行适当的质量控制后,我们测试了不同的标准化策略,如用估算和未估算数据的全局均值进行标准化、miRNA受限集的均值标准化、分位数标准化和内参miRNA标准化,以确定能最大程度降低数据中技术/实验变异性的方法。我们通过筛选出表达模式最接近样本中miRNA平均表达水平的最佳内参候选物,并使用Reffinder软件下的NormFinder、geNorm、Best Keeper和Delta Ct算法组合评估其稳定性。通过逆转录-qPCR并评估其在该队列中的稳定性排名,在同一试验的50名高血压非裔美国人中验证了四种最佳内参的适用性。在比较的标准化策略中,分位数标准化和全局均值标准化在降低基于阵列数据中各样本间miRNA标准差方面表现优于其他方法。在我们筛选过程中选出的四个最强候选miRNA(miR-223-3p、19b、106a和126-5p)中,miR-223-3p和miR-126-5p在验证队列中的稳定性排名始终最佳。此外,与单个miRNA相比,miR-223-3p和126-5p的组合显示出更好的稳定性排名。我们确定分位数标准化随后进行全局均值标准化是降低数据方差的最佳方法。我们确定miR-223-3p和126-5p的组合为高血压研究中的潜在内参。